Colon Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Patients with histologically confirmed colonic adenocarcinoma at any stage (I–IV) seeking curative resection, adjuvant chemotherapy, palliative systemic therapy, or a combination

• Patients diagnosed with high-risk Stage II colon cancer (T4 lesion, perforated tumor, <12 lymph nodes examined, poor differentiation, lymphovascular or perineural invasion, elevated preoperative CEA >5 ng/mL)

• Patients with Stage III disease (any T, N1–N2) who are candidates for R0 resection followed by adjuvant FOLFOX or CAPOX chemotherapy

• Patients with oligometastatic Stage IV disease (limited hepatic or pulmonary metastases) potentially suitable for curative-intent resection of primary and metastatic sites, including simultaneous or staged hepatectomy

• Patients with MSI-high/dMMR tumors at any stage who may benefit from immune checkpoint inhibitor therapy (pembrolizumab first-line)

• Patients seeking second opinions on treatment planning, KRAS/NRAS/BRAF/MSI molecular profiling, or enrollment in clinical trial protocols at accredited centers

• Patients with locally advanced rectal-sigmoid junction tumors evaluated for neoadjuvant short-course radiotherapy (SCRT) or total neoadjuvant therapy (TNT) prior to surgery

• REQUIRED PRE-TRAVEL DIAGNOSTIC WORK-UP:

• Colonoscopy with biopsy and histopathological confirmation (H&E staining, tumor grade)

• High-resolution contrast-enhanced CT scan of chest, abdomen, and pelvis (CT CAP) for TNM staging

• MRI pelvis (if sigmoid or rectosigmoid involvement to assess mesorectal fascia clearance)

• PET-CT scan (FDG-18) for detection of occult metastatic disease in high-risk or Stage III–IV presentations

• Serum tumor markers: CEA (carcinoembryonic antigen) and CA 19-9

• Extended molecular/biomarker panel: KRAS exon 2/3/4, NRAS exon 2/3/4, BRAF V600E, MSI/MMR by IHC or PCR, HER2 IHC/FISH, NTRK fusion testing

• Complete blood count (CBC), comprehensive metabolic panel (CMP), LFTs, coagulation profile (PT/INR)

• Echocardiogram (ECHO) and ECG for patients aged >60 or with cardiac comorbidities prior to major surgery

• Nutritional assessment (albumin, pre-albumin) and risk scoring: ASA physical status classification, Revised Cardiac Risk Index (RCRI), P-POSSUM score for surgical risk stratification

• Pulmonary function tests (PFTs) if significant lung involvement or prior smoking history

• RELATIVE CONTRAINDICATIONS (REQUIRE MDT EVALUATION):

• Uncontrolled active infection or sepsis from colonic perforation requiring emergency local stabilization before transfer

• Severe cardiac dysfunction (NYHA Class III–IV heart failure, recent MI within 3 months) without pre-operative optimization

• Extensive peritoneal carcinomatosis with Peritoneal Cancer Index (PCI) >20, indicating limited benefit from CRS/HIPEC

• Significant hepatic dysfunction (Child-Pugh B or C) precluding safe hepatectomy in synchronous metastatic disease

• Poor performance status (ECOG PS 3–4) that precludes major abdominal surgery or full-dose systemic chemotherapy

• Uncorrected severe coagulopathy

• Patient inability or unwillingness to remain in-country for minimum required post-operative follow-up period

SURGICAL APPROACHES:

1. Open Colectomy (Traditional): Midline laparotomy with segmental resection (right hemicolectomy, left hemicolectomy, sigmoid colectomy, transverse colectomy, or subtotal colectomy depending on tumor location) with complete mesocolic excision (CME) and central vascular ligation (CVL). CME is the colonic equivalent of total mesorectal excision (TME) for rectal cancer and has been shown to reduce local recurrence. Historically the standard approach; now primarily reserved for emergent presentations (obstruction, perforation), bulky T4b tumors with adjacent organ invasion, or limited laparoscopic/robotic access.

2. Laparoscopic Colectomy: Minimally invasive 4–5 port technique offering equivalent oncological outcomes to open resection for Stage I–III colon cancer (validated by landmark COST, COLOR, and CLASICC trials). Advantages include significantly reduced postoperative pain, shorter hospital stay (4–7 days vs. 7–10 days for open), faster return of bowel function, reduced wound complications, and earlier eligibility for adjuvant chemotherapy initiation.

3. Robotic-Assisted Colectomy (da Vinci Si/Xi Platform): Increasingly adopted at high-volume centers in India and the UAE. The robotic platform provides 3D high-definition visualization, 7-degree-of-freedom wristed instrumentation, and superior dexterity in confined anatomical spaces (e.g., pelvis, splenic flexure). Particularly advantageous for obese patients, complex anatomy, and left-sided or sigmoid resections. Associated with lower conversion-to-open rates compared to standard laparoscopy. Available at Apollo Hospitals, Fortis, Medanta, Aster, Cleveland Clinic Abu Dhabi, American Hospital Dubai, and Mediclinic City Hospital.

4. Transanal Minimally Invasive Surgery (TAMIS) / Transanal Total Mesorectal Excision (TaTME): Applied for distal sigmoid and rectosigmoid tumors; allows bottom-up dissection with superior visualization of the distal mesorectal plane, reducing circumferential resection margin (CRM) positivity rates.

5. Cytoreductive Surgery (CRS) + HIPEC: For selected patients with peritoneal-only metastatic disease and Peritoneal Cancer Index (PCI) ≤15–20. Involves surgical debulking of all visible peritoneal deposits followed by intraperitoneal perfusion with heated chemotherapy (typically oxaliplatin or mitomycin C at 41–43°C for 30–90 minutes). Associated with median overall survival of 30–63 months at specialized centers—a significant improvement over systemic chemotherapy alone.

6. Laparoscopic or Open Hepatectomy for Synchronous Liver Metastases: For oligometastatic Stage IV disease, curative-intent liver resection performed simultaneously or in a staged fashion after colorectal resection offers 5-year survival rates of 25–40%. Preoperative portal vein embolization (PVE) or ALPPS procedure may be employed to augment future liver remnant (FLR) volume.

SYSTEMIC THERAPY OPTIONS:

7. Adjuvant Chemotherapy (Stage III and High-Risk Stage II): FOLFOX (oxaliplatin 85 mg/m² + leucovorin + 5-FU bolus/infusion, every 2 weeks × 12 cycles) or CAPOX (capecitabine 1000 mg/m² BID D1–14 + oxaliplatin 130 mg/m² D1, every 3 weeks × 8 cycles). Duration: 3–6 months (IDEA collaboration data support 3-month CAPOX for low-risk Stage III with equivalent efficacy and reduced neurotoxicity).

8. First-Line Metastatic Chemotherapy: FOLFOX or FOLFIRI (irinotecan + leucovorin + 5-FU) as backbone, combined with bevacizumab (anti-VEGF) in all-comers or cetuximab/panitumumab (anti-EGFR) in RAS/RAF wild-type left-sided tumors. FOLFOXIRI + bevacizumab (TRIBE regimen) for fit patients with high tumor burden requiring rapid response.

9. Immunotherapy: Pembrolizumab (PD-1 inhibitor) as first-line monotherapy for MSI-high/dMMR metastatic colon cancer (KEYNOTE-177 trial: mPFS 16.5 months vs. 8.2 months for chemotherapy). Nivolumab ± ipilimumab as second-line option.

10. Targeted Therapy: BRAF V600E-mutated tumors: encorafenib + cetuximab (BEACON-CRC trial). HER2-amplified/overexpressed tumors: trastuzumab + pertuzumab or tucatinib + trastuzumab. NTRK-fusion positive tumors: larotrectinib or entrectinib (tumor-agnostic approval).

11. Radiation Therapy: Not a primary modality for colon cancer (unlike rectal cancer), but palliative radiotherapy is employed for painful bone metastases, brain metastases, or localized bleeding from unresectable primary tumors. Stereotactic body radiotherapy (SBRT/SABR) for oligometastatic hepatic or pulmonary lesions in patients not suitable for surgical resection.

12. Enhanced Recovery After Surgery (ERAS) Protocol: All major centers apply multimodal ERAS pathways including preoperative carbohydrate loading, minimization of opioid analgesia (TAP blocks, epidurals), early enteral feeding, and early ambulation—reducing hospital length of stay by 30–40% and lowering complication rates.

PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure):

• Patient submits existing medical records (pathology report, imaging, biomarker panel) to GAF Healthcare's clinical coordinator for review by the assigned colorectal oncology MDT.

• GAF Healthcare facilitates e-Medical Visa application for India (typically processed in 3–5 business days) or coordinates entry visa/visa-on-arrival for UAE destinations.

• Oncology case summary and provisional treatment recommendation prepared by the receiving hospital's tumor board and shared with patient prior to travel.

• Preadmission optimization: nutritional supplementation (high-protein oral feeds if albumin <3.5 g/dL), iron infusion for preoperative anemia correction (target Hb >10 g/dL), anticoagulation bridging plan, and cessation of antiplatelet agents per surgeon guidance.

• GAF Healthcare arranges airport reception, ground transfer, and accommodation for patient and one attendant near the treating hospital.

PHASE 2 — HOSPITAL ADMISSION & PREOPERATIVE WORKUP (Days 1–3):

• Day 1: Hospital admission, reassessment by colorectal surgeon and anesthesiologist. Repeat or additional imaging ordered if prior studies are >8 weeks old or inadequate quality.

• Day 2: Anesthesia pre-assessment (RCRI, airway assessment, ECHO review). Stoma nurse consultation if defunctioning ileostomy or permanent colostomy is anticipated. Patient education on ERAS protocol, expected postoperative trajectory, and stoma management.

• Day 3 (pre-operative): Mechanical bowel preparation (surgeon-dependent), low-residue diet, carbohydrate loading with clear maltodextrin drink until 2 hours pre-surgery, VTE prophylaxis (LMWH), and antibiotic prophylaxis plan confirmed.

PHASE 3 — SURGERY (Day 3 or 4):

• Procedure duration: 2–5 hours depending on extent of resection, approach (laparoscopic/robotic/open), and need for simultaneous hepatectomy or HIPEC.

• Intraoperative: General anesthesia with thoracic epidural or TAP block for enhanced analgesia. Intraoperative colonoscopy may be used for tumor localization. Sentinel lymph node mapping with fluorescent dye (ICG near-infrared imaging) increasingly employed at robotic centers.

• Specimen sent for urgent frozen section (margins) and definitive histopathology with full nodal harvest, lymphovascular invasion assessment, and confirmed molecular panel.

• Patient transferred to surgical HDU/ICU for 12–24 hours of close hemodynamic monitoring.

PHASE 4 — POST-OPERATIVE RECOVERY IN HOSPITAL (Days 4–14):

• Day 1 post-op: Urinary catheter removed (laparoscopic/robotic cases), oral clear liquids commenced, early ambulation with physiotherapist support.

• Days 2–3 post-op: Epidural or regional analgesia weaned; step-down to oral multimodal analgesia. Soft diet introduced. Drain output monitored for anastomotic leak or hemorrhage.

• Days 4–5 post-op: Return of bowel function confirmed (flatus/stool). Regular diet tolerated. Wound inspection. Stoma output assessed and patient/attendant trained in stoma care if applicable.

• Days 5–7 post-op (laparoscopic/robotic): Discharge criteria met if patient is afebrile, tolerating full diet, ambulating independently, and stoma/wound is stable. Oral analgesics only.

• Days 7–14 post-op (open or complex resection/HIPEC): Extended monitoring, nutritional support, and physiotherapy. Final histopathology report typically available by Day 7–10.

PHASE 5 — POST-DISCHARGE RECOVERY & ADJUVANT PLANNING (Weeks 2–6 in country):

• Week 2 post-op: Outpatient wound review, staple/suture removal. Oncologist consultation to discuss final pathology, definitive TNM stage, and adjuvant therapy plan.

• Weeks 3–4: If adjuvant chemotherapy is indicated, PICC line or port-a-cath insertion and Cycle 1 of FOLFOX/CAPOX may be initiated in-country if patient's travel timeline allows. Alternatively, a detailed written treatment protocol is provided for continuation at the patient's home country oncologist.

• Week 4–6 (Fit-to-Fly Assessment): Surgeon confirms: surgical wound fully healed, no anastomotic leak evidence, stoma functioning well (if present), no active VTE, and patient comfortable for long-haul travel. VTE prophylaxis (LMWH injections) prescribed for the flight. Comprehensive discharge summary, operative report, histopathology, and imaging CDs provided.

• Post-departure: GAF Healthcare arranges telemedicine follow-up appointments with the treating surgeon and oncologist at 6 weeks, 3 months, and 6 months post-surgery.